Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does osteopenia warrant treatment?

James A Simon1

  • 1George Washington University School of Medicine, Washington, DC 20036-5803, USA. jasimon@erols.com

Menopause (New York, N.Y.)
|September 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nocturia in postmenopausal women.

Menopause (New York, N.Y.)·2026
Same author

A Contemporary View of Menopausal Hormone Therapy: Correction.

Obstetrics and gynecology·2026
Same author

Quantification of "Mercy Sex" in Heterosexual Women.

Journal of sex & marital therapy·2026
Same author

Report of the FDA's expert panel on hormone therapy.

Menopause (New York, N.Y.)·2026
Same author

Tailoring transdermal estradiol dose to maximize benefits and minimize risks.

Menopause (New York, N.Y.)·2026
Same author

Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

AJOG global reports·2026
Same journal

Combined adductor pollicis muscle thickness and handgrip strength as predictive indicators for risk stratification of low muscle mass and low bone mass in adult women.

Menopause (New York, N.Y.)·2026
Same journal

Novel and traditional anthropometric measures of obesity association with dynapenia in postmenopausal women.

Menopause (New York, N.Y.)·2026
Same journal

Regulatory awareness, counseling priorities, and treatment choices in menopausal hormone therapy: a cross-sectional survey of obstetricians and gynecologists.

Menopause (New York, N.Y.)·2026
Same journal

Menopause Step-by-Step: must-know studies.

Menopause (New York, N.Y.)·2026
Same journal

Processed foods in the context of a vegan diet, and changes in body weight and severe hot flashes in postmenopausal women: a secondary analysis of a randomized clinical trial.

Menopause (New York, N.Y.)·2026
Same journal

Female and male factors associated with female sexual function in couples aged 50-70 years: a cross-sectional study.

Menopause (New York, N.Y.)·2026
See all related articles

Osteoporosis and osteopenia affect millions of postmenopausal women, increasing fracture risk. Early diagnosis and treatment, including antiresorptive therapy, are crucial for preventing fractures in at-risk women.

Area of Science:

  • Gerontology
  • Endocrinology
  • Orthopedics

Background:

  • Osteoporosis causes significant morbidity and mortality in postmenopausal women, with 8 million at high risk for fractures.
  • Osteopenia, though less severe, is more prevalent and poses a growing concern due to increased hormone therapy discontinuation.
  • Rapid bone loss occurs post-menopause and after discontinuing hormone therapy, elevating fracture risk.

Purpose of the Study:

  • To address the question of whether osteopenia should be diagnosed and treated before it progresses to osteoporosis.
  • To highlight the considerable consequences of failing to identify and treat women at increased fracture risk.
  • To emphasize the importance of preventing the first fracture in at-risk women.

Main Methods:

  • The study reviews existing data on osteoporosis and osteopenia prevalence and risk factors in postmenopausal women.

Related Experiment Videos

  • It analyzes the impact of hormone therapy use and discontinuation on bone loss and fracture risk.
  • It discusses the goals and therapeutic strategies for managing bone loss and preventing fractures.

    • Main Results:

    • Osteoporosis affects 8 million American women aged 50+, leading to fractures, morbidity, and mortality.
    • Osteopenia is nearly three times more prevalent than osteoporosis but often remains subclinical.
    • Bone loss accelerates significantly in the first year after discontinuing hormone therapy, increasing fracture risk.

    Conclusions:

    • Early diagnosis and treatment of osteopenia are essential to prevent progression to osteoporosis and reduce fracture risk.
    • Nonpharmacologic and pharmacologic therapies, particularly antiresorptive agents, are vital for fracture prevention in at-risk women.
    • Addressing the rising number of postmenopausal women and those discontinuing hormone therapy is critical for public health.